CRISPR Therapeutics AG
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.13%.
Did CRSP Beat Earnings? Q3 2025 Results
CRISPR Therapeutics posted a mixed but broadly encouraging set of Q3 2025 results, delivering a narrower-than-expected loss while revenue came in well short of forecasts. The gene-editing pioneer reported a loss of $1.17 per share, beating the consensus estimate of $1.29 by 9.23%, though revenue of just $889,000 missed the $8.95 million consensus by 90.07%, even as the top line grew 47.7% year over year. The central story behind the numbers was a surge in collaboration expense tied to the CASGEVY program, which ballooned to $57.12 million from $11.15 million a year earlier after a cost deferral limit that had cushioned 2024 results no longer applied, widening the net loss to $106.44 million. Institutional investors have continued to build positions in the stock, reflecting confidence in the pipeline's longer-term trajectory. With Vertex projecting clear line of sight to over $100 million in total CASGEVY revenue for 2025 and meaningful growth expected in 2026, and CTX310's Phase 1b advancement underway, CRISPR Therapeutics enters the final stretch of the year with commercial momentum building.
- CASGEVY patient momentum with 50 cell collections and 10 infusions in Q3 2025
- Nearly 300 patients referred to authorized treatment centers globally
- Cell collections in first nine months of 2025 doubled total for all of 2024
- R&D expense reduction driven by lower external research and manufacturing costs
- Italy reimbursement agreement for SCD and TDT expanding European market access
“This has been another strong quarter of execution and progress across our portfolio. CASGEVY momentum continues to build globally, reflecting growing patient engagement and clinical advancement. Enrollment has been completed in two global Phase 3 pediatric studies, and dosing is on track to complete this quarter. Additionally, positive Phase 1 data for CTX310 presented in a late-breaking presentation at the American Heart Association Scientific Sessions and published in The New England Journal of Medicine, highlight the breadth and potential of our platform to address serious cardiovascular disease. We continue to advance our broader pipeline, including dosing the first patient in the Phase 2 clinical trial of SRSD107 and unveiling our novel SyNTase editing platform with CTX460, highlighting continued innovation and expansion of our therapeutic toolkit. With strong execution and growing momentum across our programs, CRISPR Therapeutics is well positioned to lead the next wave of gene editing innovation and deliver potentially transformative therapies to patients.”
CRISPR Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
CASGEVY momentum is expected to continue accelerating, with Vertex projecting clear line of sight to over $100 million in total CASGEVY revenue for 2025 and significant growth expected in 2026. Pediatric dosing in two global Phase 3 studies is expected to complete in Q4 2025, with initial data at ASH in December 2025. CTX310 is advancing into Phase 1b clinical trials prioritizing severe hypertriglyceridemia and mixed dyslipidemia. CTX320 update is expected in H1 2026. CTX460 clinical trial initiation is planned for mid-2026. Broad updates on CTX112 in autoimmune disease and oncology are expected by year-end 2025. The Phase 2 trial of SRSD107 is expanding to additional European sites. The company also expects to provide an update on its regenerative medicine program for Type 1 diabetes later this year.
CRSP YoY Financials
CRSP Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.